

[For Immediate Release]



EuroEyes International Eye Clinic Limited

德視佳國際眼科有限公司

(Stock Code: 1846.HK)

EuroEyes Group Completes the Acquisition of FYEO Europe B.V. at an Enterprise Value of EUR 135 million

*Expects to Expand the Group's revenue base by 65% on a Pro Forma Basis
Strengthening EuroEyes' Market Position and Driving Long-Term Sustainable
Development*

(Hong Kong, 23 July 2026) – [EuroEyes International Eye Clinic Limited](#) (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, stock code: 1846), a leading global refractive surgery group, today announced that EuroEyes Netherlands (the “Purchaser”), a wholly-owned subsidiary of the Group, has completed the acquisition of [FYEO Europe B.V.](#) (“FYEO”), strategically strengthens EuroEyes’ market position in the Netherlands while expecting to expand the Group’s combined revenue base by approximately 65% on a pro forma basis, creating lasting value for the Company and its shareholders.

Under the terms of the agreement, FYEO will be acquired at an enterprise value of **EUR135 million** on a cash-free and debt-free basis. This valuation corresponds to an EV/EBITDA multiple of approximately 10.2 times based on FYEO’s unaudited reported EBITDA of approximately EUR13.17 million for FY2025. On a debt-free and cash-free basis, the equity consideration amounts to approximately EUR131.8 million. The subscription is structured on a locked box basis, with the purchase price subject to a deduction for any leakage occurring between the locked-box date and completion. The acquisition was financed through a combination of the Group's internal resources, bank borrowings, and a reinvestment by FYEO’s management team into EuroEyes Netherlands.

Supported by favourable demographics and high levels of disposable income, the Netherlands represents an attractive refractive surgery market. FYEO is focused exclusively on refractive surgery, treating patients with presbyopia and myopia through a network of 3 clinics and 10 consultation centres across the Netherlands. Over the past three years, FYEO has delivered a strong and consistent financial performance with revenue increasing from approximately EUR37.5 million in FY2023 to EUR64.0 million in FY2025, representing a CAGR of approximately 31%. Over the same period, gross profit nearly doubled to EUR24.3 million, while net profit after tax increased 169% to EUR6.2 million, demonstrating the strength and scalability of its business model.

Assuming the acquisition occurred on 1 January 2025, on a pro forma basis, the revenue of the enlarged Group would be HK\$1,314.7 million, representing an increase of approximately 65% as compared to EuroEyes' revenue. The adjusted EBITDA and profit for the year ended 31 December 2025, excluding the non-cash and one-off items that made up of the majority of the pro forma adjustments, would be approximately HK\$349.0 million and HK\$77.6 million respectively, for the enlarged Group. This represents an increase of 44.0% and 37.1% respectively as compared to EuroEyes' figures, highlighting the underlying strength and recurring profitability of the business.

EuroEyes and FYEO share a pure-play refractive surgery focus and a strong emphasis on clinical excellence and patient experience. Following the completion, FYEO will operate as a sub-brand under EuroEyes Netherlands, with its existing leadership team remaining in place.

Dr. Jørn Slot Jørgensen, Founder, Chairman and CEO of EuroEyes, said, "We are pleased to welcome FYEO to the EuroEyes Group. FYEO has built a strong name in the Netherlands, with the same values that are essential to us: quality, expertise and personal attention for every patient. Together, we see significant opportunities to further develop refractive surgery services across Europe."

Mr. Rens Schoenmakers, CEO of FYEO, said, "This step marks an important moment in FYEO's development. We will remain an organisation focused on the highest quality and personalised care. At the same time, the collaboration with EuroEyes offers the opportunity to continue to grow, learn and innovate within an international network of specialists. It is a wonderful recognition of what our team has built together."

-End-

About EuroEyes International Eye Clinic Limited (1846.HK)

EuroEyes was established in 1993 by Dr Jørn Jørgensen, an internationally recognized refractive surgeon and entrepreneur and today is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 30 years of experience with individualised patient care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Switzerland, Denmark, the PRC and the United Kingdom. The Group's vision correction services include (i) refractive laser surgery (which includes ReLEx SMILE and Femto LASIK and Presbyond®); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation). For more information, please visit ir.euroeyes.hk.

About FYEO Europe B.V.

FYEO is the largest clinic group for private pay refractive surgery in the Netherlands. FYEO offers consultations and examinations for laser and lens implantation treatments at 15 locations across the Netherlands. Since its founding in 2002, a driven and enthusiastic team of approximately 350 employees and 22 specialists has treated more than 80,000 satisfied patients. For more information, visit: <https://fyeo.nl/>